RU2676729C2 - Новый аналог инсулина и его применение - Google Patents

Новый аналог инсулина и его применение Download PDF

Info

Publication number
RU2676729C2
RU2676729C2 RU2015138536A RU2015138536A RU2676729C2 RU 2676729 C2 RU2676729 C2 RU 2676729C2 RU 2015138536 A RU2015138536 A RU 2015138536A RU 2015138536 A RU2015138536 A RU 2015138536A RU 2676729 C2 RU2676729 C2 RU 2676729C2
Authority
RU
Russia
Prior art keywords
insulin
immunoglobulin
conjugate
group
insulin analogue
Prior art date
Application number
RU2015138536A
Other languages
English (en)
Russian (ru)
Other versions
RU2015138536A (ru
Inventor
Сан Юн ХВАН
Йонг Хо ХУХ
Джин Юнг КИМ
Сунг Хее Хонг
Ин Юнг ЧОЙ
Сун Юб Чун
Се Чан КВОН
Даи Джин КИМ
Хьюн Юк КИМ
Мьюнг Хьюн ДЖАНГ
Сеунг Су КИМ
Original Assignee
Ханми Фарм. Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ханми Фарм. Ко., Лтд. filed Critical Ханми Фарм. Ко., Лтд.
Publication of RU2015138536A publication Critical patent/RU2015138536A/ru
Application granted granted Critical
Publication of RU2676729C2 publication Critical patent/RU2676729C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
RU2015138536A 2013-02-26 2014-02-26 Новый аналог инсулина и его применение RU2676729C2 (ru)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
KR10-2013-0020703 2013-02-26
KR20130020703 2013-02-26
KR10-2013-0082511 2013-07-12
KR20130082511 2013-07-12
KR20140006937 2014-01-20
KR10-2014-0006937 2014-01-20
PCT/KR2014/001593 WO2014133324A1 (ko) 2013-02-26 2014-02-26 신규한 인슐린 아날로그 및 이의 용도

Publications (2)

Publication Number Publication Date
RU2015138536A RU2015138536A (ru) 2017-04-03
RU2676729C2 true RU2676729C2 (ru) 2019-01-10

Family

ID=51428522

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015138536A RU2676729C2 (ru) 2013-02-26 2014-02-26 Новый аналог инсулина и его применение

Country Status (25)

Country Link
US (2) US20160008483A1 (pt)
EP (2) EP3616727B1 (pt)
JP (3) JP6552968B2 (pt)
KR (2) KR20140106452A (pt)
CN (2) CN104995206B (pt)
AU (2) AU2014221531B2 (pt)
BR (1) BR112015019985A2 (pt)
CA (1) CA2901873C (pt)
CL (1) CL2015002330A1 (pt)
DK (1) DK2963056T3 (pt)
ES (2) ES2868351T3 (pt)
HK (1) HK1211944A1 (pt)
IL (1) IL240717B (pt)
MX (1) MX366400B (pt)
MY (1) MY186990A (pt)
PE (2) PE20191481A1 (pt)
PH (1) PH12015501814A1 (pt)
PT (1) PT2963056T (pt)
RU (1) RU2676729C2 (pt)
SA (2) SA518400491B1 (pt)
SG (2) SG10201907106VA (pt)
TW (3) TWI755579B (pt)
UA (1) UA119533C2 (pt)
WO (1) WO2014133324A1 (pt)
ZA (1) ZA201507104B (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
AR090281A1 (es) * 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
EP3616727B1 (en) * 2013-02-26 2021-03-31 Hanmi Pharm. Co., Ltd. Insulin analog conjugates and use thereof
PE20161153A1 (es) * 2014-01-20 2016-10-27 Hanmi Pharm Ind Co Ltd Insulina de accion prolongada y uso de la misma
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
AR100695A1 (es) 2014-05-30 2016-10-26 Hanmi Pharm Ind Co Ltd Composición para el tratamiento de diabetes mellitus que comprende insulina y un agonista dual glp-1 / glucagón
KR20150140177A (ko) 2014-06-05 2015-12-15 한미약품 주식회사 단백질 및 펩타이드의 면역원성을 감소시키는 방법
JP2018508504A (ja) * 2015-02-17 2018-03-29 ハンミ ファーマシューティカル カンパニー リミテッド 持続型インスリンまたはインスリンアナログ結合体
ES2978112T3 (es) 2015-07-24 2024-09-05 Hanmi Pharmaceutical Co Ltd Método de preparación de un conjugado polipeptídico fisiológicamente activo
UY36870A (es) 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos
TW201726702A (zh) * 2015-09-24 2017-08-01 韓美藥品股份有限公司 生產胰島素之方法
BR112019005637A2 (pt) * 2016-09-23 2019-07-30 Hanmi Pharm Ind Co Ltd análogos da insulina com afinidade reduzida para o receptor de insulina e seu uso
US20200078470A1 (en) * 2016-12-05 2020-03-12 Hanmi Pharm. Co., Ltd. Conjugate with attenuated immune response
HUE055417T2 (hu) 2016-12-09 2021-11-29 Akston Biosciences Corp Inzulin-Fc fúziók és alkalmazási eljárások
KR102645064B1 (ko) * 2017-02-03 2024-03-08 한미약품 주식회사 지속성이 증가된 생리활성 물질의 결합체 및 이의 용도
KR20180091773A (ko) 2017-02-07 2018-08-16 한미약품 주식회사 비펩티드성 중합체 링커 화합물, 그 링커 화합물을 포함하는 결합체, 및 이들의 제조방법
KR101941975B1 (ko) 2017-03-17 2019-01-25 고려대학교 산학협력단 Atpif1을 함유하는 당뇨 치료용 약학조성물
CA3054899A1 (en) * 2017-03-23 2018-09-27 Hanmi Pharm. Co., Ltd. Insulin analog complex with reduced affinity for insulin receptor and use thereof
JP7377195B2 (ja) 2017-09-29 2023-11-09 ハンミ ファーマシューティカル カンパニー リミテッド リンカーとして非ペプチド性重合体結合脂肪酸誘導体化合物を含むタンパク質結合体及びその製造方法
KR20190038456A (ko) * 2017-09-29 2019-04-08 한미약품 주식회사 효력이 향상된 지속성 단백질 결합체
US11267862B2 (en) 2018-06-29 2022-03-08 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
EP3892628B1 (en) 2018-06-29 2022-09-07 Akston Biosciences Corporation Ultra-long acting insulin-fc fusion proteins and methods of use
SG11202106168VA (en) 2018-12-11 2021-07-29 Sanofi Sa Insulin analogs having reduced insulin receptor binding affinity
WO2020130751A1 (ko) 2018-12-21 2020-06-25 한미약품 주식회사 인슐린 및 글루카곤을 포함하는 약학 조성물
CN113453703A (zh) 2018-12-21 2021-09-28 韩美药品株式会社 包括胰岛素和对胰高血糖素和glp-1和gip受体均具有活性的三重激动剂的药物组合物
TWI844709B (zh) * 2019-07-31 2024-06-11 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
FI4073098T3 (fi) * 2019-12-19 2023-11-15 Akston Biosciences Corp Ultrapitkävaikutteiset insuliini-Fc-fuusioproteiinit ja niiden käyttömenetelmät
US11186623B2 (en) 2019-12-24 2021-11-30 Akston Bioscience Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
KR102545250B1 (ko) * 2020-03-31 2023-06-21 한미약품 주식회사 신규한 면역 활성 인터루킨 2 아날로그
HRP20230990T1 (hr) 2020-04-10 2023-12-08 Akston Biosciences Corporation Antigen specifična imunoterapija za fuzijske proteine covid-19 i postupci uporabe
US11192930B2 (en) 2020-04-10 2021-12-07 Askton Bioscences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
JP7532638B2 (ja) 2020-07-24 2024-08-13 チアンスー ジェンサイエンス インコーポレイテッド インスリン－Ｆｃ融合タンパク質及びその応用
EP4373861A2 (en) 2021-07-23 2024-05-29 Akston Biosciences Corporation Insulin-fc fusion proteins and methods of use to treat cancer
WO2023013640A1 (ja) * 2021-08-02 2023-02-09 Ｓｐｉｂｅｒ株式会社 多孔質体及びその製造方法
CN117769616A (zh) * 2021-08-02 2024-03-26 丝芭博株式会社 合成皮革及其制造方法
CN115894720B (zh) * 2023-01-16 2024-07-09 中国科学院上海药物研究所 一种长效胰岛素-Fc融合蛋白

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA005404B1 (ru) * 1998-10-23 2005-02-24 Амген Инк. Модифицированные пептиды как терапевтические агенты
WO2011028813A2 (en) * 2009-09-01 2011-03-10 Case Western Reserve University Insulin analogues of enhanced receptor-binding specificity
US20120071402A1 (en) * 2007-07-16 2012-03-22 Novo Nordisk A/S Protease Stabilized, Pegylated Insulin Analogues
KR20120135123A (ko) * 2011-06-02 2012-12-12 한미사이언스 주식회사 지속형 인슐린 결합체 및 지속형 인슐린 분비 펩타이드 결합체를 포함하는 당뇨병 치료용 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
EP0904107B1 (en) 1996-03-18 2004-10-20 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
DE19735711C2 (de) * 1997-08-18 2001-04-26 Aventis Pharma Gmbh Verfahren zur Herstellung eines Vorläufers von Insulin oder Insulinderivaten mit korrekt verbundenen Cystinbrücken
JP2008169195A (ja) * 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
JP5789515B2 (ja) * 2008-12-19 2015-10-07 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ インスリン類似体
AR081066A1 (es) * 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
KR101324828B1 (ko) * 2010-06-08 2013-11-01 한미사이언스 주식회사 면역글로불린 단편을 이용한 단쇄 인슐린 아날로그 약물 결합체
JP2013535467A (ja) * 2010-07-28 2013-09-12 スマートセルズ・インコーポレイテツド 組換えにより発現されたインスリンポリペプチドおよびその使用
KR101830344B1 (ko) * 2010-10-26 2018-02-22 한미사이언스 주식회사 피브로넥틴 단편 및 면역글로불린 단편의 융합 단백질 및 이의 용도
EP3616727B1 (en) * 2013-02-26 2021-03-31 Hanmi Pharm. Co., Ltd. Insulin analog conjugates and use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA005404B1 (ru) * 1998-10-23 2005-02-24 Амген Инк. Модифицированные пептиды как терапевтические агенты
US20120071402A1 (en) * 2007-07-16 2012-03-22 Novo Nordisk A/S Protease Stabilized, Pegylated Insulin Analogues
WO2011028813A2 (en) * 2009-09-01 2011-03-10 Case Western Reserve University Insulin analogues of enhanced receptor-binding specificity
KR20120135123A (ko) * 2011-06-02 2012-12-12 한미사이언스 주식회사 지속형 인슐린 결합체 및 지속형 인슐린 분비 펩타이드 결합체를 포함하는 당뇨병 치료용 조성물

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
CHEN H. ET AL., Four new monomeric insulins obtained by alanine scanning the dimer-forming surface of the insulin molecule, PROTEIN ENG., 2000, v.13, n11, p.779-782. *
CHU YING-CHI ET AL., THE A14 POSITION OF INSULIN TOLERATES CONSIDERABLE STRUCTURAL ALTERATIONS WITH MODEST EFFECTS ON THE BIOLOGICAL BEHAVIOR OF THE HORMONE, JOURNAL OF PROTEIN CHEMISTRY, 1992, v.11, n.5, p.571 - 577. *
CHU YING-CHI ET AL., THE A14 POSITION OF INSULIN TOLERATES CONSIDERABLE STRUCTURAL ALTERATIONS WITH MODEST EFFECTS ON THE BIOLOGICAL BEHAVIOR OF THE HORMONE, JOURNAL OF PROTEIN CHEMISTRY, 1992, v.11, n.5, p.571 - 577. CHEN H. ET AL., Four new monomeric insulins obtained by alanine scanning the dimer-forming surface of the insulin molecule, PROTEIN ENG., 2000, v.13, n11, p.779-782. VIGNERI R. ET AL., Insulin and its analogs: actions via insulin and IGF receptors, ACTA DIABETOLOGICA, 2010, v.47, n.4, p.271 - 278. *
FRANKEL A.E. et al., Characterization of diphtheria fusion proteins targeted to the human interleukin-3 receptor, Protein Engineering, 2000, v. 13, n. 8, p. 575-581. *
KRISTENSEN C. et al., Alanine Scanning Mutagenesis of Insulin, JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, v.272, n.20, p.12978-12983. *
TREETHARNMATHUROT B. et al, Effect of PEG molecular weight and linking chemistry on the biological activity and thermal stability of PEGylated trypsin, International Journal of Pharmaceutics, 2008, v. 357, p. 252-259. *
VIGNERI R. ET AL., Insulin and its analogs: actions via insulin and IGF receptors, ACTA DIABETOLOGICA, 2010, v.47, n.4, p.271 - 278. *
СКОСЫРЕВ В.С. и др., Зависимость стабильности гибридов зеленого флуоресцентного белка с обелином от природы составляющих их модулей и структуры аминокислотного линкера, Биоорган.химия, 2001, т.27, N 5, с.364-371. *
СКОСЫРЕВ В.С. и др., Зависимость стабильности гибридов зеленого флуоресцентного белка с обелином от природы составляющих их модулей и структуры аминокислотного линкера, Биоорган.химия, 2001, т.27, N 5, с.364-371. TREETHARNMATHUROT B. et al, Effect of PEG molecular weight and linking chemistry on the biological activity and thermal stability of PEGylated trypsin, International Journal of Pharmaceutics, 2008, v. 357, p. 252-259. *

Also Published As

Publication number Publication date
AU2014221531A1 (en) 2015-08-27
HK1211944A1 (en) 2016-06-03
EP2963056A1 (en) 2016-01-06
MX366400B (es) 2019-07-08
UA119533C2 (uk) 2019-07-10
CN104995206A (zh) 2015-10-21
JP6552968B2 (ja) 2019-07-31
PT2963056T (pt) 2020-02-19
ES2868351T3 (es) 2021-10-21
KR20140106452A (ko) 2014-09-03
BR112015019985A2 (pt) 2017-08-29
TWI755579B (zh) 2022-02-21
TW201817741A (zh) 2018-05-16
WO2014133324A1 (ko) 2014-09-04
TW201920243A (zh) 2019-06-01
RU2015138536A (ru) 2017-04-03
PH12015501814B1 (en) 2015-12-07
EP2963056B1 (en) 2019-11-13
EP3616727B1 (en) 2021-03-31
SA515360933B1 (ar) 2018-12-23
CN104995206B (zh) 2022-04-12
US20160008483A1 (en) 2016-01-14
CN114989289B (zh) 2024-10-01
PE20191481A1 (es) 2019-10-18
JP2021193089A (ja) 2021-12-23
PE20151409A1 (es) 2015-10-07
DK2963056T3 (da) 2020-02-17
IL240717B (en) 2020-05-31
SA518400491B1 (ar) 2022-04-07
CL2015002330A1 (es) 2015-12-28
SG10201907106VA (en) 2019-09-27
TW201520224A (zh) 2015-06-01
JP2016510003A (ja) 2016-04-04
JP2019187440A (ja) 2019-10-31
KR20210109491A (ko) 2021-09-06
AU2018267648A1 (en) 2018-12-13
ES2770776T3 (es) 2020-07-03
EP3616727A1 (en) 2020-03-04
US20180256731A1 (en) 2018-09-13
PH12015501814A1 (en) 2015-12-07
NZ751062A (en) 2021-04-30
MY186990A (en) 2021-08-26
TWI621626B (zh) 2018-04-21
EP2963056A4 (en) 2017-06-07
CN114989289A (zh) 2022-09-02
IL240717A0 (en) 2015-10-29
CA2901873C (en) 2022-05-03
MX2015010471A (es) 2016-04-25
TWI708782B (zh) 2020-11-01
AU2014221531B2 (en) 2018-08-23
SG11201506095TA (en) 2015-09-29
AU2018267648B2 (en) 2020-04-16
NZ710882A (en) 2021-01-29
CA2901873A1 (en) 2014-09-04
KR102413691B1 (ko) 2022-06-28
ZA201507104B (en) 2019-04-24

Similar Documents

Publication Publication Date Title
RU2676729C2 (ru) Новый аналог инсулина и его применение
AU2020277290B2 (en) Composition for treating diabetes mellitus comprising insulin and a GLP-1/glucagon dual agonist
US10253082B2 (en) Long-acting insulin and use thereof
RU2677800C2 (ru) Сайт-специфичный конъюгат инсулина
RU2779462C2 (ru) Комплекс аналога инсулина со сниженной аффинностью к инсулиновому рецептору и его применение
NZ751062B2 (en) Novel insulin analog and use thereof
NZ710882B2 (en) Novel insulin analog and use thereof
BR112016028076B1 (pt) Composição para o tratamento de diabetes mellittus que compreende insulina e um agonista dual glp-1/glucagon